Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.

have reported a similar 1.9‐fold higher risk of all‐cause mortality in patients with CHB, and an increasing trend has been observed in the mortality rate from past HBV infection (defined as anti‐core antibody seropositivity but HBsAg seronegativity) to current HBV infection compared to uninfected controls. 3 The incidence of all‐cause mortality in patients with CHB was 1.9%–2.1% per person‐year in the aforementioned two studies. 2 , 3 However, only 6%–24% of the patients with CHB received antiviral agents.

also in 63,971 other papers